176 related articles for article (PubMed ID: 32213443)
1. Correlation of levetiracetam concentration in peripheral blood mononuclear cells with clinical efficacy: A sensitive monitoring biomarker in patients with epilepsy.
Harby SA; Nassra RA; Mekky JF; Ali SM; Ismail CA
Seizure; 2020 May; 78():71-77. PubMed ID: 32213443
[TBL] [Abstract][Full Text] [Related]
2. The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy.
Gulcebi MI; Kendirli T; Turgan ZA; Patsalos PN; Onat Yilmaz F
Epilepsy Res; 2018 Dec; 148():17-22. PubMed ID: 30326332
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring in pregnancy: Levetiracetam.
Fallik N; Trakhtenbroit I; Fahoum F; Goldstein L
Epilepsia; 2024 May; 65(5):1285-1293. PubMed ID: 38400747
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring and the therapeutic reference range of levetiracetam for Chinese patients: Problems and issues.
Shi M; Liu C; He L; Wu H; Wu Y
Seizure; 2023 Jul; 109():26-33. PubMed ID: 37192596
[TBL] [Abstract][Full Text] [Related]
5. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
6. Serum levetiracetam concentrations after transdermal levetiracetam administration, 3 times daily, to healthy cats.
Smith C; Barnes Heller HL; Reif N; Van Hesteren M; Reinhart JM
J Vet Intern Med; 2019 Mar; 33(2):827-830. PubMed ID: 30663797
[TBL] [Abstract][Full Text] [Related]
7. Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting.
Reimers A; Olsson P; Nilsson J; Hoff E; Reis M; Strandberg M; Lundgren A; Källén K
Epilepsy Res; 2017 Aug; 134():54-61. PubMed ID: 28595756
[TBL] [Abstract][Full Text] [Related]
8. Saliva and serum levetiracetam concentrations in patients with epilepsy.
Mecarelli O; Li Voti P; Pro S; Romolo FS; Rotolo M; Pulitano P; Accornero N; Vanacore N
Ther Drug Monit; 2007 Jun; 29(3):313-8. PubMed ID: 17529888
[TBL] [Abstract][Full Text] [Related]
9. Review on the relevance of therapeutic drug monitoring of levetiracetam.
Sourbron J; Chan H; Wammes-van der Heijden EA; Klarenbeek P; Wijnen BFM; de Haan GJ; van der Kuy H; Evers S; Majoie M
Seizure; 2018 Nov; 62():131-135. PubMed ID: 30237016
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Drug Monitoring of Levetiracetam in Different Trimesters of Pregnant Women with Epilepsy in a Tertiary Care Center: A Prospective Study.
Kumaravel J; Sarma P; Suri V; Singh P; Prakash A; Medhi B
Neurol India; 2024 Mar; 72(2):358-363. PubMed ID: 38691482
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication.
May TW; Rambeck B; Jürgens U
Ther Drug Monit; 2003 Dec; 25(6):690-9. PubMed ID: 14639055
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and efficacy of oral loading of levetiracetam.
Koubeissi MZ; Amina S; Pita I; Bergey GK; Werz MA
Neurology; 2008 May; 70(22 Pt 2):2166-70. PubMed ID: 18505995
[TBL] [Abstract][Full Text] [Related]
13. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
14. Quality of life after switching to generic levetiracetam - A prospective comparative study.
Olsson P; Reimers A; Källén K
Epilepsy Behav; 2019 Jul; 96():169-174. PubMed ID: 31150996
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of levetiracetam in daily clinical practice: high-performance liquid chromatography versus immunoassay.
Mendoza Aguilera M; Bellés Medall MD; Álvarez Martín T; Pascual Marmaneu Ó; Liñana Granell C; Ferrando Piqueres R
Eur J Hosp Pharm; 2020 Mar; 27(e1):e2-e6. PubMed ID: 32296497
[TBL] [Abstract][Full Text] [Related]
16. [Paradoxical effect of levetiracetam on seizure suppression: three cases showing U curve association between dose and effect].
Inoue T; Kobayashi K; Usami K; Shimotake A; Inouchi M; Sakai T; Ikeda A; Takahashi R
Rinsho Shinkeigaku; 2021 Apr; 61(4):247-252. PubMed ID: 33762498
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring of Levetiracetam in Select Populations.
Jarvie D; Mahmoud SH
J Pharm Pharm Sci; 2018; 21(1s):149s-176s. PubMed ID: 30096051
[TBL] [Abstract][Full Text] [Related]
18. A novel action of lacosamide on GABA
Ruffolo G; Di Bonaventura C; Cifelli P; Roseti C; Fattouch J; Morano A; Limatola C; Aronica E; Palma E; Giallonardo AT
Neurobiol Dis; 2018 Jul; 115():59-68. PubMed ID: 29621596
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, double-dummy, multicenter trial comparing the efficacy and safety of extended- and immediate-release levetiracetam in people with partial epilepsy.
Wu T; Lim SN; Tsai JJ; Chuang YC; Huang CW; Lin CC; Hsu CH; Fung HC; Lee CH
Seizure; 2018 Nov; 62():84-90. PubMed ID: 30308428
[TBL] [Abstract][Full Text] [Related]
20. An initial experience with therapeutic drug monitoring of levetiracetam as reported from a pediatric clinical setting in India.
Mathew BS; Fleming DH; Thomas M; Prabha R; Saravanakumar K
Neurol India; 2012; 60(2):146-9. PubMed ID: 22626693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
